PH12021550759A1 - Alphavirus-based replicons for administration of biotherapeutics - Google Patents

Alphavirus-based replicons for administration of biotherapeutics

Info

Publication number
PH12021550759A1
PH12021550759A1 PH12021550759A PH12021550759A PH12021550759A1 PH 12021550759 A1 PH12021550759 A1 PH 12021550759A1 PH 12021550759 A PH12021550759 A PH 12021550759A PH 12021550759 A PH12021550759 A PH 12021550759A PH 12021550759 A1 PH12021550759 A1 PH 12021550759A1
Authority
PH
Philippines
Prior art keywords
domain
hypervariable domain
alphavirus
world alphavirus
alphavirus nsp3
Prior art date
Application number
PH12021550759A
Other languages
English (en)
Inventor
Jason L Dehart
Nathaniel Stephen Wang
Parinaz Aliahmad
Shigeki Miyake-Stoner
Kurt Iver Kamrud
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of PH12021550759A1 publication Critical patent/PH12021550759A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH12021550759A 2018-10-08 2021-04-06 Alphavirus-based replicons for administration of biotherapeutics PH12021550759A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862742868P 2018-10-08 2018-10-08
PCT/US2019/055125 WO2020076775A1 (en) 2018-10-08 2019-10-08 Alphavirus-based replicons for administration of biotherapeutics

Publications (1)

Publication Number Publication Date
PH12021550759A1 true PH12021550759A1 (en) 2021-12-13

Family

ID=68343515

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12021550759A PH12021550759A1 (en) 2018-10-08 2021-04-06 Alphavirus-based replicons for administration of biotherapeutics

Country Status (17)

Country Link
US (1) US12331076B2 (enExample)
EP (1) EP3864027A1 (enExample)
JP (2) JP7846986B2 (enExample)
KR (1) KR20210074314A (enExample)
CN (1) CN113227122B (enExample)
AU (1) AU2019359204B2 (enExample)
BR (1) BR112021006614A2 (enExample)
CA (1) CA3115480A1 (enExample)
CL (1) CL2021000855A1 (enExample)
CO (1) CO2021006453A2 (enExample)
EA (1) EA202190907A1 (enExample)
IL (1) IL282043A (enExample)
MA (1) MA53858A (enExample)
MX (1) MX2021004032A (enExample)
PH (1) PH12021550759A1 (enExample)
SG (1) SG11202103167VA (enExample)
WO (1) WO2020076775A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
EP3986458A1 (en) * 2019-06-20 2022-04-27 Janssen Sciences Ireland Unlimited Company Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof
MX2022013638A (es) * 2020-04-30 2023-01-24 Vlp Therapeutics Inc Inmunoterapia con citocina.
KR20230009489A (ko) 2020-05-11 2023-01-17 얀센 파마슈티칼즈, 인코포레이티드 안정화된 코로나 바이러스 스파이크 단백질을 암호화하는 rna 레플리콘
JP2024527345A (ja) * 2021-07-09 2024-07-24 リプリケイト バイオサイエンス，インコーポレイティド 改変東部ウマ脳炎ウイルス、自己複製ｒｎａ構築物、及びその使用
EP4376883A4 (en) * 2021-07-30 2025-07-16 Arcturus Therapeutics Inc RNA VACCINES
CN113846113B (zh) * 2021-09-09 2022-09-13 臻赫医药(杭州)有限公司 一种有限自我复制mRNA分子系统、制备方法及应用
CN115785250A (zh) * 2021-09-10 2023-03-14 清华大学 用于抑制委内瑞拉马脑炎病毒生物活性的蛋白及其应用
US11510975B1 (en) * 2021-11-29 2022-11-29 Replicate Bioscience, Inc. Compositions and methods for inducing ESR1, PI3K, HER2, and HER3 immune responses
CN114317563B (zh) * 2021-12-17 2023-09-05 华南理工大学 提高基因表达的rna复制子及其应用
EP4511497A4 (en) * 2022-04-19 2026-04-22 Replicate Bioscience Inc MODIFIED WESTERN EQUINE ENCEPHALITIS VIRUS AND ITS USES
CN116179603B (zh) * 2022-09-30 2024-10-29 中国科学院深圳先进技术研究院 稳定表达外源基因的sinv载体及其制备方法和应用
WO2025017036A1 (en) * 2023-07-17 2025-01-23 Institut National de la Santé et de la Recherche Médicale Alphavirus nsp3 helical tubular scaffolds
CN118147171B (zh) * 2024-03-08 2024-12-06 上海复诺健生物科技有限公司 具有增强的外源基因表达水平的自扩增mRNA核酸序列
CN121586776A (zh) * 2023-07-19 2026-02-27 上海复诺健生物科技有限公司 自扩增核酸分子及其应用
AU2024381228A1 (en) 2023-11-13 2026-05-28 Ziphius Nv MODIFIED ALPHAVIRAL nsP3
CN118086395B (zh) * 2024-04-25 2024-06-21 南京农业大学三亚研究院 一种盖塔病毒质粒载体、弱毒株及其制备方法和应用
CN119639774B (zh) * 2024-12-13 2026-05-29 杭州剂泰生命科技有限公司 自复制rna分子组合及其应用

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
EP0091539B2 (en) 1982-03-31 1996-11-27 Ajinomoto Co., Inc. Gene coding for interleukin-2 polypeptide, recombinant DNA carrying said gene, cell lines possessing the recombinant DNA,and method for producing interleukin-2 using said cells
US4966843A (en) 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4892743A (en) 1983-12-21 1990-01-09 Schering Corporation Novel hybrid interferon species
EP0165942A1 (en) 1983-12-23 1986-01-02 Monash University PRODUCTION OF HUMAN INTERFERON-$g(a)
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
CA2004261A1 (en) 1988-12-01 1990-06-01 Charles T. Tackney Synthetic interleukin-6
US5225337A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
US5246921A (en) 1990-06-26 1993-09-21 The Wistar Institute Of Anatomy And Biology Method for treating leukemias
US5780036A (en) 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
ATE227118T1 (de) 1993-08-02 2002-11-15 Scripps Research Inst Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus
SE9401709D0 (sv) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US6041252A (en) 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
DE19712889A1 (de) 1997-03-27 1998-10-01 Bosch Gmbh Robert Verfahren und Vorrichtung zur Ermittlung einer den Systemdruck in einem Bremskreis beschreibenden Größe
WO1998043702A2 (en) 1997-04-03 1998-10-08 Iacob Mathiesen Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US5873849A (en) 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
GB0023203D0 (en) 2000-09-21 2000-11-01 Isis Innovation Vaccination method
US6117660A (en) 1997-06-10 2000-09-12 Cytopulse Sciences, Inc. Method and apparatus for treating materials with electrical fields having varying orientations
CA2294793A1 (fr) 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede
US5958060A (en) 1998-01-02 1999-09-28 General Electric Company Method and apparatus for clock control and synchronization
EP2428250A1 (en) 1998-07-13 2012-03-14 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6319901B1 (en) 1998-10-15 2001-11-20 Ichor Medical Systems, Inc. Methods for prolonging cell membrane permeability
US20040213805A1 (en) 1999-10-12 2004-10-28 Verheije Monique Helene Deletions in arterivirus replicons
WO2002020721A2 (en) 2000-09-07 2002-03-14 University Of North Carolina At Chapel Hill Vectors derived from south african arbovirus no. 86
US6538922B1 (en) 2000-09-27 2003-03-25 Sandisk Corporation Writable tracking cells
HU230198B1 (hu) 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
WO2002061113A2 (en) 2001-02-01 2002-08-08 The Johns Hopkins University Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
CA2448066A1 (en) 2001-05-31 2002-12-12 Chiron Corporation Chimeric alphavirus replicon particles
ATE354260T1 (de) 2001-07-19 2007-03-15 Ericsson Telefon Ab L M Verfahren und vorrichtung für die lösung der nummernübertragbarkeit am ursprungsort
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
WO2004055161A2 (en) 2002-12-12 2004-07-01 The Board Of Regents Of The University Of Texas System Large scale production of packaged alphavirus replicons
US8080255B2 (en) 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
PT1651666E (pt) 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
US20050070700A1 (en) 2003-09-30 2005-03-31 Matthias Giese Equine arteritis virus vaccine
KR101261642B1 (ko) 2004-03-08 2013-05-06 아이커 메디칼 시스템스 인코포레이티드 치료 제제의 전기 매개식 이송을 위한 개선된 장치
PT1751289E (pt) 2004-05-18 2009-03-31 Alphavax Inc Vectores de alfavirais derivados da tc-83, partículas e métodos
US20090104226A1 (en) 2004-05-21 2009-04-23 Novartis Vaccines And Diagnostics Inc. Alphavirus Vectors for Respiratory Pathogen Vaccines
AU2005327198B2 (en) 2004-07-09 2011-03-31 University Of North Carolina At Chapel Hill Viral adjuvants
EP2029747A4 (en) 2006-06-06 2011-01-05 Melbourne Health PROOF AND USE OF ANTIVIRAL RESISTANCE MUTATIONS
EP2062246A4 (en) 2006-08-18 2010-09-29 Univ North Carolina VACCINES AGAINST CHIMARICAL VIRUSES
AU2007313203B2 (en) 2006-10-17 2012-08-16 Vgx Pharmaceuticals, Llc Electroporation devices and methods of using same for electroporation of cells in mammals
EP2097538A4 (en) 2006-12-07 2011-11-30 Switchgear Genomics TRANSCRIPTION REAGULATION ELEMENTS OF BIOLOGICAL PATHS, TOOLS AND METHODS
KR100836745B1 (ko) 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
DK2947149T3 (en) 2007-06-21 2018-06-06 Alphavax Inc ALPHAVIRUS REPLICATION PARTICLES FOR USE IN VACCINATION
US20110110974A1 (en) 2007-10-29 2011-05-12 Erik Depla Methods and kits for inducing a ctl response using a prime boost regimen
CA2770075C (en) 2009-08-07 2021-08-24 Perrine Martin Composition for treating hbv infection
WO2011082388A2 (en) 2009-12-31 2011-07-07 Medigen, Inc . Infectious dna vaccines against chikungunya virus
PT3243526T (pt) 2010-07-06 2020-03-04 Glaxosmithkline Biologicals Sa Distribuição de arn para despoletar múltiplas vias imunitárias
AU2011349464B2 (en) 2010-12-20 2016-07-07 The General Hospital Corporation Polycomb-associated non-coding RNAS
US9403879B2 (en) 2011-02-11 2016-08-02 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding hepatitis B virus core protein and vaccine comprising the same
DK3473296T3 (da) 2011-06-28 2020-11-09 Inovio Pharmaceuticals Inc Minimalt invasiv dermal elektroporeringsenhed
TWI575070B (zh) 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
AU2013266496B2 (en) * 2012-05-21 2018-08-09 The Regents Of The University Of California Generation of human iPS cells by a synthetic self- replicative RNA
US8961995B2 (en) 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons
EP3178505B1 (en) 2012-12-13 2018-05-02 Panasonic Healthcare Holdings Co., Ltd. Medicament injection device
WO2014170493A2 (en) 2013-04-19 2014-10-23 Novartis Ag Alphavirus vector
AU2014310935B2 (en) 2013-08-21 2019-11-21 CureVac SE Combination vaccine
WO2016020538A1 (en) 2014-08-08 2016-02-11 Transgene Sa Hbv vaccine and antibody combination therapy to treat hbv infections
KR102586707B1 (ko) 2014-10-01 2023-10-11 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항원 및 어쥬번트로서 인터류킨-21을 갖는 백신
PL3280729T3 (pl) 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
DK3294326T3 (da) 2015-05-15 2021-05-31 Curevac Ag Prime-boost-regimer indbefattende indgivelse af mindst én mrna-konstruktion
JP7048482B2 (ja) 2015-08-03 2022-04-05 アメリカ合衆国 Ｂｒａｃｈｙｕｒｙ欠失変異体、Ｂｒａｃｈｙｕｒｙ欠失変異体をコードする非酵母ベクター、及びそれらの使用
NZ747635A (en) 2016-03-28 2024-05-31 Ichor Medical Systems Inc Method and apparatus for delivery of therapeutic agents
WO2017176319A1 (en) 2016-04-06 2017-10-12 University Of Washington Therapeutic vaccine for hepatitis b virus (hbv) using the hbv core antigen
JP7250520B2 (ja) 2016-04-13 2023-04-03 ヤンセン ファーマシューティカルズ，インコーポレーテッド 組換えアルテリウイルスレプリコン系およびその使用
ES2993107T3 (en) 2016-10-17 2024-12-23 Janssen Pharmaceuticals Inc Recombinant virus replicon systems and uses thereof
JP7788787B2 (ja) 2016-12-05 2025-12-19 ヤンセン ファーマシューティカルズ，インコーポレーテッド 遺伝子発現増強のための組成物および方法
CN110612118B (zh) 2017-06-05 2024-02-13 比科尔公司 用于引起针对hbv的免疫应答的病毒样粒子
CN117866990A (zh) 2017-11-16 2024-04-12 华盛顿大学 使用HBV包膜蛋白的HBV PreS1和/或PreS2和/或S-HBsAg区域的治疗乙型肝炎病毒（HBV）的疫苗
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
MA51311A (fr) 2017-12-19 2020-10-28 Janssen Sciences Ireland Unlimited Co Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
EA202091516A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)

Also Published As

Publication number Publication date
CA3115480A1 (en) 2020-04-16
US12331076B2 (en) 2025-06-17
MA53858A (fr) 2021-09-15
WO2020076775A1 (en) 2020-04-16
CL2021000855A1 (es) 2021-11-26
MX2021004032A (es) 2021-07-06
EP3864027A1 (en) 2021-08-18
US20200109178A1 (en) 2020-04-09
BR112021006614A2 (pt) 2021-07-20
CN113227122A (zh) 2021-08-06
JP7846986B2 (ja) 2026-04-16
JP2025160243A (ja) 2025-10-22
AU2019359204B2 (en) 2024-12-05
AU2019359204A1 (en) 2021-04-29
CN113227122B (zh) 2025-05-06
EA202190907A1 (ru) 2021-06-25
CO2021006453A2 (es) 2021-05-31
JP2022512625A (ja) 2022-02-07
KR20210074314A (ko) 2021-06-21
SG11202103167VA (en) 2021-04-29
IL282043A (en) 2021-05-31

Similar Documents

Publication Publication Date Title
MX2021004032A (es) Replicones basados en alfavirus para la administracion de bioterapeuticos.
US11826416B2 (en) Induce and enhance immune responses using recombinant replicon systems
WO2014170493A3 (en) Alphavirus vector
MX2021005254A (es) Produccion recombinante de una preparacion de peptido de colageno y uso de la misma.
MXPA05010007A (es) Replicones de alfavirus y construcciones auxiliares mejorados.
IL291100B1 (en) RNA replicon for diverse and efficient gene expression
UA124343C2 (uk) Капсиди аденоасоційованого вірусу і спосіб його використання
ES2746960T3 (es) Partículas de replicón de alfavirus que codifican IL-12 como adyuvantes inmunológicos
PH12019500068A1 (en) Novel adeno-associated virus capsid proteins
MY191030A (en) Gdf15 fusion proteins and uses thereof
PH12022550767A1 (en) Hbv vaccines and methods treating hbv
JP2007537761A (ja) Ｔｃ−８３由来アルファウイルスベクター、粒子および方法
EA023888B1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
PH12019502010A1 (en) Coronaviruses, vaccines comprising the same, and methods for preventing disease
NZ743236A (en) Fmdv and e2 fusion proteins and uses thereof
Maruggi et al. Engineered alphavirus replicon vaccines based on known attenuated viral mutants show limited effects on immunogenicity
AR114942A1 (es) Partícula de replicón de alfavirus
WO2019079663A8 (en) Artificial secretion peptides for heterologous protein production
MX2015007093A (es) Composiciones y metodos para el tratamiento de canceres cerebrales.
AR121961A1 (es) Inmunoterapia con citocina
MY190078A (en) Improved method for producing virus like particles
PH12018502460A1 (en) Arthrogenic alphavirus vaccine
WO2012073045A3 (en) Variants of trappins
CA3009928A1 (en) Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine
WO2010097709A3 (en) Polypeptides for the prevention or treatment of malaria